3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM)
Phase of Trial: Phase IV
Latest Information Update: 22 Aug 2018
At a glance
- Drugs Eluxadoline (Primary)
- Indications Irritable bowel syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Allergan
- 31 Aug 2018 Biomarkers information updated
- 13 Aug 2018 Planned End Date changed from 27 Jul 2018 to 20 Jan 2019.
- 13 Aug 2018 Planned primary completion date changed from 20 Jul 2018 to 20 Jan 2019.